Comparative Pharmacology
Head-to-head clinical analysis: THORAZINE versus TRIFLUOPERAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THORAZINE versus TRIFLUOPERAZINE HYDROCHLORIDE.
THORAZINE vs TRIFLUOPERAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system, reducing dopaminergic neurotransmission. It also has antiemetic effects via dopamine blockade in the chemoreceptor trigger zone and possesses anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
5-10 mg orally twice daily (maximum 40 mg/day), or 1-2 mg intramuscularly every 4-6 hours for acute symptoms (maximum 10 mg/day).
None Documented
None Documented
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Terminal elimination half-life: 12–24 hours; clinical context: requires 5–7 days to reach steady state; may be prolonged in elderly or hepatic impairment
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Primarily renal (approximately 70% as metabolites, <1% unchanged); fecal (approximately 30% via bile)
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic